{"id":"vdcld-regimen","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of the VDCLD regimen is not well understood, but it is believed to work by targeting rapidly dividing cancer cells and inhibiting their growth. The regimen is a combination of multiple drugs, each with its own mechanism of action, which together provide a synergistic effect to treat cancer.","oneSentence":"The VDCLD regimen is a combination of chemotherapy drugs used to treat various types of cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:22.272Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Small cell lung cancer"},{"name":"Head and neck cancer"},{"name":"Esophageal cancer"},{"name":"Gastric cancer"},{"name":"Breast cancer"},{"name":"Colorectal cancer"},{"name":"Pancreatic cancer"},{"name":"Gastrointestinal stromal tumor"}]},"trialDetails":[{"nctId":"NCT03419494","phase":"","title":"Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2013-10-10","conditions":"Adult Acute Lymphoblastic Leukemia","enrollment":40},{"nctId":"NCT02070523","phase":"PHASE3","title":"Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:","status":"UNKNOWN","sponsor":"Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.","startDate":"2013-12","conditions":"Acute Lymphoblastic Leukemia","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":204608,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VDCLD regimen","genericName":"VDCLD regimen","companyName":"Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.","companyId":"changzhou-jinyuan-pharmaceutical-manufacturing-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The VDCLD regimen is a combination of chemotherapy drugs used to treat various types of cancer. Used for Non-small cell lung cancer, Small cell lung cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}